Epithelial Cytokines in the Spotlight

Prefer to attend in person? Register for our livestream at ExchangeCME.com/CRSwNPLosAngelesLive

Program Description

Please join us for dinner and a dynamic Science in the Spotlight symposium featuring expert panelists Drs. Joseph Han, Stella Lee, and Rohit Katial as they examine evolving management approaches for chronic rhinosinusitis with nasal polyps (CRSwNP), with a focus on biologics targeting epithelial-derived cytokines in the airways, including thymic stromal lymphopoietin (TSLP), interleukin-25 (IL-25), and interleukin-33 (IL-33). This program brings together perspectives from allergy, immunology, and otorhinolaryngology to explore the how these epithelial alarmins drive the inflammation, airway dysfunction, and disease persistence seen in patients with CRSwNP.

Through a focused whiteboard animation, case-based checkpoints, and interactive faculty dialogue, the engaging, multidisciplinary faculty panel will guide participants through both an examination of epithelial cytokine signaling in CRSwNP and practical therapeutic decision-making involving new and emerging biologic therapies that target alarmin cytokines. In addition, attendees will also learn about the latest clinical evidence for newer and emerging biologic therapies targeting epithelial alarmin-driven inflammation and discuss how to incorporate these novel therapies into mechanism-based treatment strategies, with an emphasis on optimizing disease control, escalating treatment as needed, reducing the need for oral corticosteroids and endoscopic sinus surgery, reducing symptom burden, and improving the quality of life experienced by patients living with CRSwNP.

Target Audience

This educational activity has been designed to educate ear, nose, and throat specialists as well as clinical immunologists/allergists and pulmonologists who manage patients with CRSwNP.

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

1. Describe the roles of epithelial cytokine signaling in the pathogenesis of CRSwNP, including implications for patient evaluations and treatment
2. Assess patients with CRSwNP for symptom burden, psychosocial effects, comorbidities, and treatment responses
3. Discuss the clinical profiles and evidence for biologic therapies that target epithelial cytokines in the treatment of CRSwNP
4. Escalate treatment appropriately for CRSwNP to address underlying pathophysiologic processes, improve disease control, and reduce the need for oral corticosteroids or endoscopic sinus surgery

Program Agenda

6:00 pm Preactivity Questionnaire and Faculty Introductions
6:10 pm Early Signaling in CRSwNP
6:30 pm Comprehensively Evaluating Patients with CRSwNP
6:45 pm Evolving Management of CRSwNP
7:15 pm Key Takeaways, Recap, Postactivity Questionnaire, and Q&A Session

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must attend the live symposium/live stream and complete the posttest and program evaluation.

Disclosures of Conflicts of Interest

Integritas Communications adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

The Integritas planners and managers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this activity.

Americans With Disabilities Act

Any activity registrant who feels s/he may need accommodation based on the impact of a disability should contact Integritas at info@exchangecme.com to discuss their specific needs.

Integritas Contact Information

For information about this program, please contact us at info@exchangecme.com.